Ezra Cohen to Imidazoles
This is a "connection" page, showing publications Ezra Cohen has written about Imidazoles.
Connection Strength
1.647
-
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 12; 74(6):1261-70.
Score: 0.461
-
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 09 01; 120(17):2694-703.
Score: 0.448
-
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008 Oct 10; 26(29):4708-13.
Score: 0.297
-
Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy. Cancer Lett. 2015 Apr 10; 359(2):269-74.
Score: 0.118
-
Pharmacokinetics of single-agent axitinib across multiple solid tumor types. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1279-89.
Score: 0.115
-
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck. 2012 May; 34(5):736-45.
Score: 0.091
-
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res. 2011 Jun 01; 17(11):3841-9.
Score: 0.091
-
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
Score: 0.026